Episode Details
Back to Episodes
Wound Healing Modulation 2026: Anti-fibrotics in Filtering Surgery
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/wound-healing-modulation-2026-anti-fibrotics-in-filtering-surgery
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Wound Healing Modulation 2026: Anti-fibrotics in Filtering Surgery Glaucoma filtering surgeries (like trabeculectomy or tube shunts) lower eye pressure by draining fluid out of the eye into a tiny reservoir or bleb under the conjunctiva. After surgery, the eye’s natural wound-healing response (scarring) can close off this drainage, causing the surgery to fail. To prevent excessive scarring, surgeons use anti-fibrotic medications during or after surgery. The most common agents are Mitomycin C (MMC) and 5-fluorouracil (5-FU). These drugs help keep the drainage channel open, improving long-term success. For example, in one study about 95% of eyes reached targets at 6–12 months after trabeculectomy with either MMC or 5-FU (). In other words, both drugs greatly boost the chances of success. Over the past decades and into 2026, new strategies have appeared alongside MMC and 5-FU. Rho-kinase (ROCK) inhibitors and anti-VEGF injections are emerging as wound-healing modulators. Research (in animals and small trials) suggests these may further reduce scarring in filtration surgery () (). In all cases, surgeons balance the benefits of better pressure control against risks of a very thin or leaking bleb (which can lead to infection). Below we summarize the evidence on dosing, outcomes, and safety of these therapies through mid-2026. Anti-Fibrotic Medications: How and How Much Mitomycin C (MMC) Mitomycin C (MMC) is a potent anti-scarring drug originally used in chemotherapy. In glaucoma surgery, it is applied as eye drops or soaked sponges under the conjunctiva at the time of surgery. Standard practice (for many years) is to use MMC at about 0.2 to 0.4 mg/mL concentration for 1–3 minutes on sponges covering the scleral flap area. (For example, the FDA-approved kit “Mitosol” provides 0.2 mg/mL and directs surgeons to apply saturated sponges for 2 minutes ().) In practice, surgeons tailor the dose: a routine case might get 0.2 mg/mL for 2 minutes, while a high-risk case (see risk section below) might get 0.4–0.5 mg/mL. After soaking, the area is rinsed with fluid to stop the drug’s action. Example dosing: In one clinical trial, surgeons applied MMC 0.2 mg/mL for 2 minutes versus 5-FU 50 mg/mL for 5 minutes during trabeculectomy (). Another study on the new PRESERFLO microshunt used 0.2–0.4 mg/mL MMC, lowering mean eye pressure from 21.7 to 14.1 mmHg at 2 years (). Patients given the higher 0.4 mg/mL dose were more likely to be off all medications at 2 years. MMC is very effective at keeping the bleb draining, giving excellent long-term pressure control in many patients (). In the 5-year study above, average pressure with MMC was 9.9 mmHg (from 25.8 pre-op) (), and success was high. However, MMC carries notable risks because it creates a thin, avascular (poorly blood-supplied) bleb. In that same study, about 15% of eyes developed late bleb leaks and 5.7% had blebitis (infection of the bleb) by 5 years (). Very low pressure (hypotony, <6 mmHg) occurred in 42% of eyes. In another study, most MMC-treated blebs became avascular (lack normal blood vessels) within a year, and leak risk increased over time (). Patients must be warned: a thin bleb can leak fluid and even harbor germs. Overall, bleb-related infection after MMC-augmented filtering surgery is uncommon but real – roughly 1–2% per year () () (for example, one surv